[18F]-FEPPA...............T74
mPFC...............M48, M193
1000 Genomes Project...............T213
1H MRS...............16.3, M195, M214, T40, T131, W163
22q11...............T208
22q11 mitochondria...............10.4
22q11.2 CNV...............T92
2-Deoxyglucose...............W164
31P Magnetic Resonance Spectroscopy...............4.2, W184
3-hydroxykynurenine...............M161
5CSRTT...............M141
5HT2...............M218
5-HT2A receptor...............49, 49.2, W239
7-Tesla...............W205
A
ABIDE................T150
Accumbens................3.3, M48, M193
ACE................M137
Acetaminophen................T96
Acetylcholine................T64, T69
Acoustic Startle................M192
Actigraphy................M71
Actin Remodeling................M241
Activated Microglia................W3
Acute and Chronic Stress................7.1, 26, 26.2, M53, M211, T149, W11, W60, W85
Acute Stress................M2, M213, T49, T72, T218, T257, W9
Adaptive Behavior................W9, W69
Adaptive Immunity................T142
Adaptive Testing................32.2
Addiction................29, 29.4, 36, 36.2, 36.4, 39, 40.2, 44, 44.2, 44.4, 46.3, 52, 52.1, 57.3, M139, M164, M222, M237, M242, M251, T46, T241, T256, T261, W233, W240, W250, W264, W265
Adhesion Molecules................31.2
Adiponectin................M31
Adipose Tissue................T121, W147
Adjunctive Treatment................W118
Adoelscent Academic Performance................T265
Adolescence................8, 8.2, 13.3, 13.4, 23.1, 29, 29.2, 29.3, M17, M26, M59, M97, M106, M188, M226, M266, T12, T13, T60, T202, W24, W40, W215, W224, W241
Adolescent Alcohol................9.1, M34, M46, M258, T196, W22
Adolescent Alcohol Exposure................W223
Adolescent Depression................1.3, 42.1, M107, T89, W36, W52, W59
Adolescent Development................13, M79, W213
Adolescents................8.1, 8.3, M110, M228, M236
Adrenergic Receptor................2.1
Adult Anxiety................9.1
Adult Hippocampal Neurogenesis................M75, T37, T92
Adverse Childhood Events................T137, W5
Adversit................y42
Affective Disorders................15, 40
Affective Neuroscience................M94
Age Effects................33.3, M22, W53, W55
Aggression................30, 30.1,30.2, 30.4, 40.3, T16, W84
Aging................M3, T64, T139, W183
Aging And Dementia................17.3, M4, M37, T63
Agitation................M246
Ahhedonia................41
AKT1/ AKT3................W132
Alcohol................6.1, 40.2, 46, 46.1, M222, M239, M249, T256, T264, W133, W224, W226, W229
Alcohol Abuse................T196
Alcohol and Substance Use Disorders................W233
Alcohol Consumption................46.4, M233, W261
Alcohol Dependence................40.2, 40.4, 44.2, 44.4, M125, M262, T221, T230, T237, T245, T263, W236, W255
Alcohol Exposure................W140
Alcohol Intake................T228, T231
Alcohol Preferring P Rats................W225
Alcohol Relapse Treatment................44.3
Alcohol Self-Administration................44.3, M233, T230, T255
Alcohol Use................T265
Alcohol Use Disorders (AUD)................11.2, 40, 40.1, M202, M224, M233, M249, T54, T236, T254, W235
Alcohol Withdrawal................46.2
Alcoholism................M264
Alcohol-Seeking Behavior................M242, M254
Allelic Bias Analysis in RNASeq................M267
Allometry................M27
Allopregnanolone................M76
Alpha 1A, Alpha 1B, 5-Ht1A, And 5-Ht2A Receptors................T132
Alternative Splicing................T35, T177
Altitude................M72
Alzheimer's Disease................M36, M37, M177, T95, W135
AMPA Glutamate Receptors................13.2, 14.1, 33, 43.4, W106
AMPA Receptors................M184, T207, W78, W238
Amphetamine................52.3, M135, M234, T147, T229, W182
Amygdala................7, 9.1, 18.4, 42.3, 46.1, M143, T2, T9, T10, T14, T22, T60, T70, T71, T75, T77, T81, W7, W61, W98, W255
Amygdala-Based Networks................13.1, M107, T258
Amyloid................T63, W37
Amyloid Precursor Protein................W130
Anandamide................M226, W199
Anesthetic................W95
Anhedonia................1.1, 15.2, 26.1, 41.2, M200, T89, W52, W72, W115, W237
Animal Models................12.4, 24.4, 40.3, 51.3, 58.3, 59.4, M95, M102, M118, M227, T24, T118, T181, T200, W90, W258, W264
Ankryin-G................W90
Ankyrin................W148
Anorexia Nervosa................54.4, M40, W23, W41, W42, W43, W146
Antemortem................M38
Anterior Cingulate Cortex................16.2, M28, M55, M141, T40, T144, T170, T268, W116
Anterior Prefrontal Cortex................T4
Anthranilic Acid................M161
Antibody................T155
Anti-Brain Antibodies................47.4
Antidepressant Agents................M118, W73, W102
Antidepressant Response................M99, T20, T137
Antidepressant Treatment Practice................M85, M93
Antidepressant Trials................5.4
Antidepressant................s5, 56.2, M78, M124, T121, W60, W88, W95, W101
Antimicrobials................47.2
Antipsychotic Agents................T24
Antipsychotic Induced Weight Gain................M31, T84
Antipsychotic Medication................T189, W185, W210
Antipsychotic Treatment................M151, W180
Antipsychotic-Associated Obesity................T186
Antipsychotic-Naïve First-Episode Schizophrenia................59.1, M179, T166, W199
Antipsychotics................49.2, 55.4, M86, M163, M168, M169, M173, M176, M177, M180, M181, T179, T181, T186, W173, W194
Antisocial Personality Disorder................30.1, M160
Anxiety................1.2, 1.3, 5.1, 12, 24, 24.1, 26, 31, 31.2, 31.3, 39.4, 40.3, 54, 54.2, 54.4, M13, M17, M63, M75, M106, M108, M171, T1, T2, T5, T9, T27, T49, T54, T63, T70, T76, W11, W19, W98, W100, W104, W124
Anxiety Circuitry................T6, T77, W70
Anxiety Disorder................s11, M16, M122, W48
Anxiety State................T65
Anxious Depression................T33
Apathy................T157, W120, W157
APD-Induced Metabolic Disease................1.4
Apo................E55.2, M36
Apoer................255.2
Apoptosis................M258, T130
Appetite................W65, W82
Approach-Avoidance................W112
Arc................T34, T46
Aripiprazole................T246
Aripiprazole Once-MonthlyT116
Artificial Intelligence................W127
Artificial Learning................T265
AS3M................T20.4
ASCT-2 transporter................56.2
Aspirin................W160
Assessment................32.2
Associative-Striatum................T192
Astrocytes................22.3, 29, 29.3, 43, 43.1, 43.2, 43.3, 43.4, T244, W207
ATAC-seq................W172
At-Risk................T245, W64, W110
Attention................26.1, M141, T69, W64, W139
Attention Deficit Hyperactivity Disorder (ADHD)................30, 30.1, 30.4, M24, M29, M47, M221, M252, T17, T82, T102, T147, T266, W48, W49, W124, W129, W245
Attentional Bias................M243
Atypical Antipsychotic Drug................W105
Atypical Antipsychotics................1.4, M93, T211, T246, W63, W114
Audition................M208
Auditory................W189
Auditory Cortex................M214, T36
Auditory Deficits In Schizophrenia................M201, W170
Auditory Hallucinations................M186, M194, M206, W178
Auditory Short-Term Memory................M201
Autism................22.4, 51, 51.3, 58, 59, 59.4, M25, M146, M156, M158, M192, T80, T82, T150, T153, W33
Autism & Depression................48.1
Autism Spectrum Disorders (ASD)................2.2, 22, 22.1, 50.2, M22, M23, M30, M153, T35, T85, T87, T97, W25, W27, W31, W32, W143, W148, W156
Autoimmune Encephalitis................47
Automated Computational Language Speech Faces................W191
Automated Memory-Screening Test................T94
Autopsy Brains................W176
Avoidance................3.3
Axon Guidance Molecule Genes................T154, W153
Axonal Transport................T172
Axons................W185
Aβ42................W135
B
Baby Schema................W243
Baby-Cry................M108
Baclofen................T264
Bariatric Surgery................W137
Basal Ganglia................10.2, 46.3, 54.2, M164, T148
Basolateral Amygdala................13.2, M9, M20, W225
Bath Salts................W256
Bayesian Inference................M194
BDNF................M82, M97, M155, M223, T83, T251, W102, W113, W121
BDNF Delivery................W150
Bed Nucleus Of The Stria Terminalis................12.4, 26.2, T77, T230, W19, W122
Behavior................53, 53.2, 56.1, T106, T141, T176, W33, W233
Behavioral Analysis................W209
Behavioral Despair................1.1
Behavioral Flexibility................T263
Behavioral Inhibition................T198
Behavioral Pharmacology................T20, T48, T95, T232, T266
Bench-To-Bedside................44
Beta Arrestin................T148
Beta-Amyloid Peptide 1-42................M36
Big Five Personality Factors................M67, W158
Binge Drinking................M249, T223, W221
Binge Eating................T98, T100, T102
Binge Eating Disorder................T101
Biobanks50.4
Biobehavioral Effects................T264
Biochemistry................W209
Bioenergetics................W184
Bioinformatics................M26
Biological Marker................W204
Biomarkers................4.1, 5.4, 6, 6.1, 6.2, 21.2, 23.2, 32, 38, 47.1, M4, M30, M83, M85, M91, M105, M204, T85, T87, T137, T245, W10, W51, W88, W135, W182
Biotype................W204
Bipolar................M199, M207
Bipolar Depression................T31
Bipolar Disorder................1.2, 23.1, 36.1, 38.3, 50, 50.3, M79, M81, M90, M94, M106, M109, M110, M116, M125, T30, T62, T130, T133, T160, T162, T190, T193, T200, T209, T217, W57, W58, W64, W80, W90, W105, W110, W114, W162, W212
Bipolar I Disorder................T116
Blood................M87, W2
Blood-Brain Barrier................44.1, 47.3, 47.4, T29
Body Weight................T121
BOLD imaging................T4, W75, W110, W154, W243
Borderline Personality Disorder................M160, T158, T159
Brain................20, 50.3, M27, M87, W67, W69
Brain Based Markers for Depression................17.2, 21.4
Brain Development................7.1, 8, 13.4, 22, 42, 61.1, M21, T14, W172
Brain Imaging................37, M108, W167, W203
Brain Initiative................37
Brain pH................T200
Brain Stimulation................17.1, 17.3, M206, M222, W15
Brain Structure................W220
Brain Tissue................W175
Brain Transcription................20.4
Brain-Derived Neurotrophic Factor................W73
Brexpiprazole................T171, T199, W118
Brodmann are................a25, M74
Bulimia Nervosa................61.2, M42, T15, W40, W44
Buprenorphine................T49, T114
Buprenorphine-Naloxone................M231
Bupropion................M85, W260
C
C_ SSRS................W128
CA3 Metaplasticity................2.4
Cachexia................W146
CACNA1C................M109
Caffeine................W256
Calcium................2.1, 43.1, W200
Calcium Imaging................24.2, M58, M109, T55, T233, W47, W70, W222
California Verbal Learning Test................T133
Callosotomy................W149
CAM................T152
Camk2a................T209
Camp Signalling................W102
Cancer................T152
Cannabidiol................M245, T220, W202
Cannabinoid Receptor................8.4, W158
Cannabinoids................29.4, 46.3, T250, W258
Cannabis................29.1, 29.4, 57.2, M246, T267, W227, W242, W267
Cannabis Dependence................M216, M225, T185, T220, T234
Cannabis Use................8.3, 29, 29.2, 29.3, M228, M236, T265
Cardiovascular................M110, W100
Cardiovascular Disorders................W166
Cariprazine................T163, T165
Cas9................35.1
Caspase Cascades................M258
Cat................W66
Catecholamine Depletion................M42
Caudate................M169
Causal Modeling................53.4
CB1................46.1
CBT................T111
Cdk5................15.4
Ceftriaxone................M152
Cell Adhesion Molecules................22.1, W166
Cell Transplant................10.3
Central Amygdala................W221, W223
Central Autonomic Network................W89
Central Nervous System................T211, W129
Central Nucleus Of The Amygdala................40.4
Cerebellum................51.1, 51.2, 51.3, M156, T143
Cerebral Blood Flow................M28, M42, T267
Cerebrospinal Fluid................M65, W181, W218
CESD Score................T119
CGRP................T155
Child Offspring................W35
Childhood Adversity................15.1, T136, W81
Childhood Maltreatment................23.3, 60.3, W6, W109
Childhood Trauma................16.1, T11, T81, T89, T242
Childhood-Onset Schizophrenia................T191, W205
Children................42.2, M24, W27
Children and Adolescents................M21, M31, M32, T9, T14, T84, W35
Chimeric Protein................W266
Choice................W252
Choline................M266, T90
Cholinergic Function................M149
Cholinergic Syste................m5, 5.1
Choroid Plexus................38.4
Chromatin................9.3, 52.2, W172
Chronic Mild Stress................1.1, T108
Chronic Pai................n19, T238, W147
Chronic Social Defeat................60.1
Chronic Stres................s60, T24, T121, T124, T127, W117
Cilia................M247
Cingulum................T12
Circadian Rhythm................T217
Classification................W99
Classifier................53.1
Clathrin Nanoparticles................W150
Clinical High Risk................42.1, M162
Clinical Practice................W77
Clinical Trial Design................M209, W127
Clinical Trial Methodology................M78, M134, M209, T125, W127
Clinical Trial Rating Methods................M78, T101
Clinical Trials................4.3, 45, M16, M61, M78, M81, M129, M174, M176, M181, T161, W71, W152, W262
Clozapine................M217, T168, T210
Clustering................W99
CNS Clinical Trials................M134, T240, W127
CNV................20.1
Cocaine................18.3, 36.2, 39.1, 43, 43.3, 43.4, 52.1, 52.3, M124, M229, M238, M256, M265, T46, T52, T105, T225, T227, T256, T257, W230, W257
Cocaine Addiction................3.1, M223, M241, M243, M259, T48, T57, T61, T240, T242, T247, T252, T258, T262, W228, W237, W252
Cocaine Seeking................54.3, M227, M232, M250, T233, T239, W234, W263
Coexpression Network................50.3, T26
Cognition................4.3, 8.2, 17, 17.3, 24, 34, 36.4, 49.2, 51.1, 51.2, M116, M156, M168, M208, M255, T88, T91, T160, T166, T167, T175, T185, T207, T210, T251, W174, W179, W208, W211, W212, W258
Cognitive Aging................M2
Cognitive Control................24.3, 61.2, M212, T16, T111, T192, W116, W174
Cognitive Control Network................61.1
Cognitive Decline................17
Cognitive Disorder................29, 48
Cognitive Enhancement................M138, M145, T145, T197, W189
Cognitive Functionin................g8, 8.3, M60, M140, W12, W33
Cognitive Impairments................T93, T178, T181, W120
Cognitive Neuroscience................T16
Cognitive Training................M145, W182
Cognitive/Emotional Task Performance................W50
Cognitive-Behavioral Therapy................M55, T25, T143, W142
Colony Stimulating Factor-1................T21
Community Based Family Study................42.1
Community Detection................T32
Co-Mobidity................T223
Co-Morbid................T196
Complement................T141
Complex Systems................53.4
Complicated Grief................W2
Compulsive Eating................T100
Compulsive Models Of Drug Use................T259
Compulsivity................M242, M254
Computational Modeling................3.4, 11.3, W190
Computational Neuroscience................11.1, 11.4, T241, T244
Computational Psychiatry................11.2, 11.4, 53, M230, W79, W190
COMT................T92, W152, W195
COMT Gene................W8
COMT Inhibitor................M138, M172
Conditioned Cues................W225, W253
Conditioned Place Preference................9.3, W226
Conduct Problems................30.2
Conflict Monitoring................W112
Connectivity................3.4, 42, 42.4, T9, T36, W42, W72
Connectivity-Based Parcellation................T43, T252
Connectome................M14, W138, W186
Context................39.2, W17
Continuation Phase................M80
Coping................W86
Copper Metabolism................M210
Corollary Discharge................W170
Cortical Circuit Development................59.2, T170, W213
Cortical Dysplasia................58.1
Cortical GABA................16.1, W52
Cortical GABA Transaminase................M157
Cortical Inhibition................48.2, T113
Cortical Maturation Delay................M47
Cortical Plasticity................4.4, 22.3, M26
Cortical Thickness................W109, W159, W177
Cortico-Mesolimbic Couling................W171
Corticosteroids................M2
Cortico-Striatal Circuit................T172, W216
Cortico-Striatal Plasticity................T143
Corticotropin-Releasing Factor (CRF)................40.4, T69, W221, W266
Cortisol................M73, M137, M238, T49, W53
Cortistatin................T83
COX-1 and COX-2................W1
CPP................W257
CPP-115................M157
Craving................M264, T151, T220, T257, W232, W252
C-Reactive Protein................M100
CREB................26.1
CRHBP Knockout Mice................W266
CRISPR................35.1, 35.3, T110, W148
CRMP2................T193
Cross-Generational Transmission................57.2
Cross-Sensitization................T223
CRP................38.2
CSF................W135, W220
CSF Biomarkers................32.1
Cue Reactivity................M239, T227
Cue Reinstatement................M250
Curriculu................m28, W125
CUS................M119
Cyclobenzaprine................W134
CYP2C19................M69
Cytochrome P450s................W144, W145
Cytokines................31.1, 58, 58.4, M57, M192, T52, T128, T168, W76, W181
D
D1 Dopamine Receptor................s51, M250
D1-D2 Dopamine Receptor Heteromer................M245
D2 Dopamine Antagonists................T179
D2 Receptor................54.1
D3 Receptor................M182
Dab................155.1
Dacc................M45, T71
D-amino Acid Oxidase................57.1
DAT1 Gene................M253, T254
Data Integration................50.4
Data Sharing................M134, T80
Data Transparenc................y45
DBS................M96
De Novo Mutation................T97
Death Domain................M258
Death Receptor Expression................M258
Decision Making................12, 12.1, 41.4, M228, M240, M248, W46, W227, W242
Deep Brain Stimulation................6.3, 21.1, M67, M95, T98, T122, W13, W54, W116, W143
Default Mode Network (DMN)................21, 21.4, T18, T268, W21, W24
Delay Discounting................M230, T219
Delta9-Tetrahydrocannabino................l8.2, T224
Deltafosb................M256
Dementia................T156
Dendrite................M247
Dendritic Spines................58.2, M175, M191, M223, T67, T222, W200
Dendritic Translation................14.4
De-Novo................M25
Dentate Gyrus................M75, T20, T79, W20, W62
Depression................1.2, 5.1, 5.2, 5.3, 6.4, 9, 9.2, 14.1, 14.2, 14.3, 15.1, 15.4, 16, 17.2, 21.2, 21.3, 32.4, 33, 40.1, 48, 56.4, 57, 57.4, 60.1, 61.3, M50, M52, M53, M57, M60, M61, M62, M63, M66, M68, M69, M71, M72, M75, M82, M89, M91, M100, M106, M108, M123, T21, T22, T27, T32, T78, T106, T107, T109, T111, T115, T118, T124, T128, T132, T138, T140, T141, W48, W51, W61, W65, W67, W71, W75, W76, W79, W85, W87, W92, W95, W96, W100, W104, W114, W123, W263
Desensitization................T51
Development................59, M198
Developmental................7
Developmental Pharmacology................M86
Developmental Psychopathology................M28
Developmental Trajectories................34.1
Dextromethorphan/Quinidine................W74
Diabetes................M148
Diet................W137
Diet Induced Obesity................M44
Diffusion Spectrum Imaging................M215
Diffusion Tensor Imaging................M59, M94, M99, M100, M162, M224, M259, W161
Diffusion Weighted Imaging................M45, T79, T192
Dimensional................W30
Dimensions Of Psychosis................W203
Disability................M207, W107
DISC................127.1, T172, T212, W207
Disease Model................M196
Disinhibition................W157
Disruptive Mood Dysregulation Disorder................W124
dlPFC................T45
DNA Methylation................9.4, 55.4, M62, M104, M191, T17, T30, T39, T56, T177, W98, W230, W240
Domestication................W66
Dopamine................11.2, 24, 24.2, 31, 31.1, 36.1, 36.3, 36.4, 41.4, 44.1, 54.1, 55.4, 60.1, M1, M46, M54, M138, M169, M193, M194, M211, M220, M232, T24, T55, T58, T59, T61, T163, T165, T179, T181, T186, T188, T202, T233, W45, W69, W86, W131, W159, W194, W201, W246, W247, W254
Dopamine (D2, D3) receptors................M264, T169, T179, W140, W194
Dopamine D1-D2 Receptor Heteromer................M256
Dopamine D2 Receptor................W249
Dopamine D3 receptors................W106
Dopamine Receptor Type 2-Expressing Striatal Medium Spiny Neuron................T157
Dopamine Receptors................51.1, M245
Dopamine Transporter................M260, T17, T246
Dopaminergic System................T188
Dorsal Attention Network................T44
Dorsal Raphe................7.1
Dorsal Raphe Serotonin Neurons................M84
Dorsal Striatum................54.2, W47, W222
Dorsolateral Prefrontal Cortex................M117, M249, W28, W177
DRD2................W236
DREADD Receptor................51.1
DREADD................s13, M244, T239
Drive For Activity................W23
Drug Abuse................M263, W258
Drug Cues................M243
Drug Discovery - New Approache................s25, 25.1, 25.2, 33, 49.4, M51, T148, T228, W73, W151
Drug Discovery/Development................W126
Drug Naive................T84
Drug-Protein Interactions................M152
Drugs................W94
D-Serine................43.3, 56.2, 57.1
DTI................M79, T12, W103, W114, W149
Dynamic Connectivity................3.2, 41.3, M14
Dynorphin................M232, T47
Dysbindin................M205, M210
Dyskinesia................M154
Dyspnea................T1
E
Early Life Stress................9, 9.2, M57, M64, T23, W6, W39, W98, W100, W121
Early Parental Loss................T205
Early Phase Drug Development................M11
Early Psychosis................10.1, M190, W186, W214
Early Rearing................W39
Eating Disorders................M43
eCOA................M165
Ecological Momentary Assessment................M73
ECT................21.3, M70, M217
EE................G16, 17.3, 36.3, 36.4, 41.1, W219
EEG Biomarkers................21.3, M14, M236, M243
Effect Size................M78
Effective Connectivity................M70
Efficacy and Tolerability................W58
Electric Field Modeling................W36
Electroconvulsive................W143
Electroconvulsive Therapy................6.4, M88, T117, T123, W96
Electroencephalography................M201
Electron Microscopy................T38
Electronic Cigarette (E-Cigarette)................T151, T226, T234
Electrophysiology................13.3, M5, M15, M30, M84, M184, T45, T50, T163, T166, T216, W56, W139, W167, W221, W222, W253
EMBARC................W99
Emotion................T175
Emotion Perception................W191
Emotion Processin................g30, M114, M200, W110
Emotion Regulation................11.4, M79, T14, T16, W55, W64
Emotional Reactivity................W12
Emotional Response Inhibition................T11
Endocannabinoids................8.4, 31, 31.3, 46, 46.2, 46.4, M190, M226, T5, T72, T127, T248, W199
Endogenous Opioids................T129, W83
Endophenotypes................W203
Endpoint Reliability................M165
Energy Homeostasis................W23, W62
Engram................W20
ENIGMA Working Group................M47
Entropy................M127
Environmental Enrichment................9.4, 58.3
Environmental Risk Factors................T205, W31
Epidemiology................60.3, M91, M235, M237, W219
Epigenetic Regulation................55, W172
Epigenetic................s2, 2.3, 5.3, 7.2, 9, 9.2, 9.4, 15, 15.4, 18.4, 31.4, 39.3, 50.1, 52, 52.1, 52.3, 57, 57.1, 57.2, 57.3, 57.4, M49, M64, M265, M266, T39, T126, T187, T221, T225, T262, W39, W100, W240
Epilepsy................M30, T83, W154
Episodic Memory................M36, T81, W79
Epistasis................W80
eQTL................20.3
ER Stress................W25
ErbB4 Pathway................59.2
ERK................T26, T85
ERP................W170, W189
Escitalopram................M85
Escitaropram................M69
Esketamine................56, 56.3, 56.4, M113, M115, M121, T134
Estradiol................18.3, 46.2
Estrogen................T64
Estrogen Receptor................7, 7.1, 18.4, W25
Ethanol................T260
Ethanol-Seeking................W225
Ethics................35.3, M67, M142
Event Related Potentials................M212, M216
Evoked Response Potential................24.4, M214
Excitabilty................W111
Excitatory Synapses................14, 22.1, 22.3
Executive Function................M198, W5, W186
Exercise................T76
Exome Sequencing................T249
Expectation................11.3
Experimental Design................W92
Experimental Therapeutics................33.4, 52
Extended Amygdala................26.2, M13
Extended Reward Network................41.1, 41.2, T146
Externalizing Disorders................42.3
Extinction................39.2, 39.3, M92, T227
Extinction Learning................M136, M263
Extinction Recall................M136
Extracellular Matrix Protein................s55
Extracellular Vesicles................T142
Eye-Tracking................M243, W32
F
Face Emotion Processing................T44, T117, W124, W169
Facial Expression................53.2
Familial Risk................W236
Fast-acting Antidepressant................W62
Fatigue................T152
Fatty Acids................W43
Fear................18.4, M7, M10
Fear Conditioning................7.4, 11.3, 12.2, 26.3, M6, M92, T3, T8, T66, T71, W16, W19, W70
Fear Extinction................26.3, 39, M18, M20, T3, T5
Fear Generalization................26.3, W20
Fear Memory................39.3
Fear Renewal................M136
Fear-Potentiated Startle................W19
Female................M124
Ferret................W206
Fetal fMRI................M143
Fetal Neurobehavior................M39
Fetal Programming................7.3, W265
Fibroblasts................49.3
First Episode Schizophrenia................M199, T40, W174, W196, W198, W216
First-Episode Psychosis................T182, W173, W208, W217
FKBP5................M106
Fluoxetine................M124
fMRI Biomarkers................34.3
fMRI Effective Connectivity................40
fMRI Functional Connectivity................11.1, 13, 21.4, 29.2, T196
fMRI Negative Affective Stimuli................7.3
fMRI Resting State................41.3, M110, M159, T162, W149
FMRP................T201
Food Preferences................M41
Food-Reinforced Instrumental Task................T157
Forced Swim Test................M54, M72, T112
Fox................W66
FRET................M256
Frontostriatal................21.2
Fronto-Striatal Networks................M17, T184
Functional Capacity................T190, T197
Functional Connectivity................13.4, 30.2, 30.3, M143, M186, M234, T43, W210
Functional Magnetic Resonance Imaging (fMRI)................3.1, 3.3, 11.3, 16, 16.2, 30.2, 30.4, 40.3, 41.1, 54.1, 61.2, M17, M34, M40, M43, M61, M68, M88, M100, M103, M108, M114, M127, M131, M132, M172, M178, M200, M221, M239, M242, M253, M262, T9, T11, T15, T32, T54, T60, T62, T71, T75, T106, T117, T137, T173, T191, T227, T246, T268, W16, W17, W41, W55, W64, W69, W124, W137, W158, W174, W195, W197, W198, W201, W242, W247, W252, W260
Functional Network Connectivity................M98
Functional Neuroimaging................41.2, 61, M145, W12, W76, W89, W115, W138, W145
Functional Organization................49.1
Functional Outcome................M207
Functioning................T160, W33
Funding................37
G
G Protein................M251
G Protein Coupled Receptors................M187, W94
G Protein Signaling................5
GABA................4, 4.4, 10, 13.3, 14, 46.1, 48, 48.1, 48.4, M6, M50, M97, M144, M179, M195, T70, W133, W201
GABA Neuron................M193
GABAA................48.3
GABA-A Receptors................M184, T221, W151
GABAergic Interneurons................10.2, 10.3, 14.1, 27.2, T83, W117, W131, W222, W225
GABRA2................M267
Gabra5 Conditional Knockout Mice................48.3
GAD................T177
Gambling................W45, W46
Gambling Disorder................M240, T57
Gamma Oscillation................24, T165, T183
Gamma Oscillation; Clinical Symptom Type and Severity................T190, W189
Gaussian Mixture Model................T166
Gaze Fixation................W27
GC-Insensitive Monocytes................31.2, W11
Gene Association................W179
Gene Editing................35.3
Gene Environment Interaction................20.2, 38.2, M167, M267, W43, W121
Gene Expression................50.1, M27, M49, M126, T30, T177, T230, W34, W177, W193, W195, W228, W237
Gene Network Analysis................T10, T56, T228
Gene Set Analysis................W80
Generalizability................M129
Genetic................T41
Genetic Architecture................W161
Genetic Correlation................W4
Genetic Mouse Models................2.3, 59, 59.1, M241, T42, W34, W156
Genetic Risk Factor................T37
Genetic Testing................M37
Genetic Variability................M140, T213
Genetics................20.2, 40.1, 50, 50.4, 60, 60.3, M23, M25, M30, M160, M257, T178, T204, T261, W144, W212
Genome-Editing................35.1
Genome-Wide Association................W187
Genome-Wide Association Studies (GWAS)................60.2, M140, M257, T66, T100, T119, T213, T236
Genomics................5.4, 20.3, 25, 25.3, 50, 50.1, 50.4, M52
Geriatric Depression................M126
Ghrelin................W82
Giftedness................M25
Ginkgo Extract................T93
GLP-1 Receptor Agonist................T186
GLT-1................T256, W230
Glucocorticoid Receptor................12.3, M106, T30, T70, T128, W60
Glucocorticoids................M7, M77, T10
Glucose Metabolism................W158, W184
GluN2A Recepter Subunit................T91
Glutamate................14, 16.1, 31.1, 32.4, 33, 33.2, 33.3, 43, 43.1, 43.3, 43.4, 46.1, 59.1, M32, M50, M54, M128, M179, M195, M199, M205, M213, T23, T40, T70, T78, T86, T89, T207, T251, T268, W74, W196, W210
Glutamate Gaba................16.3, M125, M203
Glutamate Homeostasis................M152
Glutamate Receptor Activity................M12
Glutamate Receptor Function................55
Glutamatergic Synapses................43.2
Glutamatergic Transmission................M44, M262
Glutathione (GSH)................4, 4.3
GLYX-13................14.3, 33.1, T78
Gonadal Hormones................18, 18.2, W22
GPCR................49.4, T148, W102, W246
GR Chaperone................M20
Graph Theory................24.3, W109, W158
Gray Matter Concentration................T242
Gray Matter Density................M188, W204
Gray Matter Volumes................W236
Group ICA................3.2
Growth Mixture Modeling................W180
GSK3................W111
GT-tg Mouse Model................W150
Gut Microbiome................1, 1.1, 1.2, 1.3, 1.4, 18.3, M102, T88, T226, W67
Gut-Brain Axis................38
GWAS LOCI................20.4
Gyrus Rectus................W42
H
Habenula................M24, T127, T235
Habit................46
Habituation................T158
Hallucinogens................M131, W168
Haplotypes................M267
Harm Reduction................W262
HDAC................T225
HDAC 2/3................T221
Head-To-Head Clinical Trial................M231
Healthy Subjects................M182, W202
Heart Rate Variability................W10, W89
Heritability................60.3, M189, W219
Heroin................M229, T232
High Frequency Oscillations................W171
High Throughput Screenin................g25
High-Throughput................25.3
Hippocampal Function................10.1, 15.2, W168
Hippocampal Hyperactivity................2.4
Hippocampal Subfields................M38, W205
Hippocampal Volume................10.1, M171, W7, W205
Hippocampus................2.1, 9.4, 38.4, 48.1, 57.1, M62, M88, T12, T27, T39, T81, T136, T139, W113, W117, W121, W196, W210
Hippocampus Shrinking................W108
Hippocampus-Mpfc Pathway................24.1, T6, T149
Hispanic/Latinos................T65
Histone................8.2
Histone Methylation................7.2, 9.1, 52.2
HIV................M19, M60, M255, T13, T128
HIV Associated Neurocognitive Disorder................W150
Homeostasis................T216
Homeostatic Synaptic Transmission................14.4
HPA................M137
HPA Axis................12.3, 23.4, M74, M123, T218, W39, W60
HPSC................25.3
Hub Analysis................M45
Human Brain Slice................T183
Human Clinical trial................M35, T78
Human Embryonic Stem Cells................10.4
Human Genetic................W266
Human Laboratory Study................M268, T264
Human Neuroimaging................3, 6, 7.4, 24.3, M3, M236, M237, M240, T13, T88, W7, W30, W40, W49, W162, W186, W251
Humans................T145, W139, W199, W226
Hunger and Satiety................M40, T102
Huntingtin................T172
Hydroxynorketamine................14.2, 56.2, W78
Hyperarousal................T218
Hypothalamic-Pituitary-Adrenal Axis................M2
Hypothalamus................M155
Hypoxia................M72
I
IL17................58.1
IL-1b................T108
Imaging................T203, W164
Imaging Genetics................T180, T246, W145, W201, W203
Immune................38.3
Immune Markers................58, M192
Immune Mechanisms................M101, T10, T29, W31
Immune Modulation................M126
Immune System................W81
Immunological................T187
Importance of Religion................W108
Impulsive Sensation Seeking................41, 41.1
Impulsiveness................T258
Impulsivity................M128, M230, M252, T57, T103, T171, T259, W13, W47, W81, W159, W238
In Vitro Neuronal Differentiation................25.1
Inattentive Symptoms................T102
Inbred Mouse Strains................T42
Incentive Motivation................61.3, T50, W201
Incentive Salience................3.4, 12.3
Individual Differences................3.1, 12.3, M131, W56
Individual Items................T195
Individual Items of Positive and Negative Syndrome Scale................T173
Induced Pluripotent Stem Cells (iPSCs)................10.4, 20.1, 25, 25.1, 25.2, M109, M183, W106
Infancy................M7, T88
Infant................42, 42.3, M39, T90
Infection................47, 58.2, M192, T90, W136
Inferior Frontal Gyrus................W21
Infertility Treatment................W88
Inflammasome................M102
Inflammation................31.1, 31.3, M26, M52, M83, M85, M89, M100, T128, T168, T208, W3, W76, W87, W92, W96, W104, W146, W160, W183, W237
Inflammatory Markers................31, 38.1, 38.2, W65
Inflammatory Pain................M130
Inflammatory Response System................T206
Infralimbic Cortex................39, 39.1, M118
Inhibition................W20
Inhibitory Control................3.1, 48.1, M40, M234, T15, W47
Inhibitory Neurotransmission................W26
Inhibitory Synaptic Transmission................14.4
Insight................W157
Insoluble Proteins................W176
Insomnia................M71, T218
Insula................M6, T1, W75, W254
Insula Connectivity................W251
Insulin................M44, W101
Insulin Resistance................M107, T211, W38, W62
Insulin-Like Growth Factor 1................M44, T67, T212
Integrin................T222
Intellectual Disability................2.2
Intelligence Quotient................M127
Intergenerational Transmission................W39
Interleaved TMS/fMRI................T4, W103
Internal Capsule................M95
Interoception................T1, W75
Interpeduncular................M244
Interpeduncular Nucleus................T235
Intracerebroventricular................T211
Intracranial EEG................W149
Intracranial Self-Administration................W223
Intracranial Self-Stimulation................M260
Intranasal................T134
Intravenous Drug Self-Administration................T46
Intravenous Immunoglobulin................47.4
Irritability................30.2
Isomirna................W188
Item Response Theory................32.2
IV Alcohol................M233
J
Japanese................M69
K
Kappa Opioid Receptor................M130, T47, T230, T247, W228, W246, W249
KCC2................W151
Ketamine................6.1, 6.2, 14, 14.2, 14.4, 15.2, 23.2, 32.4, 33.2, 56.2, 56.3, 56.4, M16, M56, M66, M80, M92, M109, M114, M115, M121, T19, T25, T31, T33, T112, T135, W59, W78, W97, W101
Kinase Inhibitor................T255
KO Mice................M112
Kv3 Family................27.1, T161, T181, T183
Kynurenine................W57
Kynurenine Metabolism................W92
L
Lactate................T200
Lactate Shuttle................M197
Language................T88
Large Scale Networks................3, M45, W138, W154
Late-Life Depression................M99, M103, T63, T65, T123, T139, W68, W120, W135
Latency of Acoustic Startle................T204
Lateral Habenula................M41, T239
Lateral Hypothalamus................M41
Lateral Orbitofrontal Cortex................T99
Lateral Septum................W131
L-DOPA................M154
Learning................17.1, W69
Learning And Memory................31.4, 59, M49, T79, T133, W22
Lethality................W248
Leukocyte Telomere Length................M3, T124
Life Stress................15
Light Therapy................M63, T107
Limbic Cortex................10, M74
Linguistic................53.1
Lipid Rafts................W102
Lipids................M90
Lipoprotein Receptors................55.1
Lisdexamfetamine................T101, W129
Lithium................M116, T62, T115, T156
Lithium Treatment................T62
Local Field Potentials................6.3, T98
Locomotion................T249
Locus Coeruelus................M63, T109
Long Noncoding RNA................T35
Long Term Potentiation................57.1, W241
Long-Acting Injectable Antipsychotic................T116
Longitudinal................M162, T84, W174
Longitudinal Imaging................W40, W149
Long-Term Depression................46.3, T224
Long-Term Potentiation................M171, T149
Low-Dose Antagonism................T145
Lurasidone................M81, W58, W91, W105, W117, W215
Lymphocytes................T85
Lysergic Acid Diethylamide................M187
M
Machine Learning................11, 53, 53.2, M91, T98, W142, W161
MADRS................W93
Magnetic Resonance Imaging (MRI)................6.4, M186, M188, T150, T265, T267, W29, W40, W72
Magnetic Resonance Spectroscopy................M6, M144
Magnetic Seizure Therapy................21, 21.3, T28
Maintenance Treatment................M163, T116, T199, W105
Major Depression................41.2, 48.4, M56, M65, M92, M102, T29, T112, T117, T123, W82
Major Depressive Disorder (MDD)................21.1, 41.3, M32, M55, M83, M88, M101, M104, M105, M114, M117, M119, M120, M129, T23, T25, T26, T31, T119, T125, T129, T134, T135, T136, T137, W24, W53, W73, W74, W78, W83, W89, W91, W93, W97, W99, W108, W118
MAM................T208
Mania................W91
MAPK................................................................55.1
Marijuana................8, 8.1, M132, M235, M245, M261, T250, T253, W258
Massage................T152
Maternal Abuse................2.3
Maternal Behavior................42.4, M7, M155
Maternal Deprivation................13.1
Maternal Immune Activation................58.1, 58.3, M39
Maternal Sensitivity................M108
Maternal Separation................13.2
Matrix Metalloproteinase-9 (MMP-9)................T222
Mechanism of Action................M58
Medial Amygdala................W61
Medial Forebrain Bundle................M67, M96, T122, W54
Medial Geniculate................T36
Medial Prefrontal Cortex................12.2, 13.2, 24.4, M171, M248, T8, T55, T131, T226, W94
Medication................M8
Medication Adherence................W127
Medication Resistance................M217
Medicinal Marijuana................8.1, M235
Mediodorsal Thalamus................24.4, M15
Medium Spiny Neurons................54.3
MEG................M214
Mega-Analysis................M47
Melanocortin................W255
Melatonin................T112
Memantine................W189
Memory................52.2, T149, W4
Memory and Learning................2.1, 48.3, 59.4, T27, T69
Memory Consolidation and Extinction................39.4, T3
Memory Encoding and Retrieval................2, W17, W168
Memory Organization................T133
Memory Reconsolidation................W234
Menopause................15.1
Mental Disorder................M183, T37
Mental Health................53.3, M133
Mental Set Shifting................M261
Menthol................W264
Meta-Analysis................M101, T103, W6, W12
Metabolic Defect................M197
Metabolic Side Effects................T186
Metabolic State................T15, W62
Metabolic Syndrome................36.1
Metabolism................M68, T86, W147
Metabolites................W141
Metformin................W38
Methamphetamine................36.2, 52.2, T234, T241, T261, W232, W250
Methotrexate................M174
Methylation................M253, W236
Methylphenidate................M29, T147, W245
Metyrapone................T68
Mexican Population................T194
Mglu 2/3................T95
Mglu2/3 Antagonist................M251
Mglur5 Receptors................M128, W44
Mice................M82, T20, W8
Microbiota-Gut-Brain Axis................W233
Microdialysis................27.2, T46, W45
Microglia................31.1, 58.4, T21, T209, T217, W11, W213
Microglia Priming................M33, M77
Microglial Activation................T260
MicroRNA (miRNA)................5.4, 50.3, 52.1, 60.2, T109, T142, T262, W188
Microtubule................W148
Migraine................T155
Mild Cognitive Impairment................T94
Mild Cognitive Impairment Due To AD................M36, W38
Mild Traumatic Brain Injury................W130, W218
Mismatch Negativity................16.3
Mitochondria................54.3, M64, T38, T86
Mitochondrial DNA................M123
Mitochondrial Dysfunction................T93
Mixed Features................W91
MMN................W189
Mobile Health................W123
Mobile Technology................W51
Mode................l26
Model-Free and Model-Based Learning................11.2, T241
Molecular Mechanisms................56, T41
Monkey................36.4
Monoamine Oxidase-A................M160, T120
Monoamines................36, 36.3, 36.4, T120
Mood................M68, T102, W66
Mood And Anxiety Disorders................7, 33.4, M16, M49, T8, W73, W81, W111
Mood Disorder Subtypes................M98
Mood Disorders................7.3, 11, 23, M59, M166, T108, T156, W55, W86, W88
Mood Dysregulation................42
Mood Stabilizers................M93
Moral Judgment................30.3
Morphine................T51, W246, W249, W257
Morphology................M175, M247
Mossy Fiber................T209
Motivated Drug Taking................39.3
Motivation................24.2, 31, 41.4, M130, T105, T157, T198, W69, W165
Motor Activity................17.2
Mouse................W139
Mouse Behavior................M20, T42
Mouse Models................5.1, 5.2, 59.2, 59.3, M187
Movement Disorders................M150, M151
MR Imaging................T22, T139, W34
MR Spectroscopy................16, 16.2, T23, T89
mRNA Expression Gradients................M203
MRS................33.2, 33.3, M179
mTOR................14.3
Multi-Electrode Arrays................25.2
Multi-Episode Schizophrenia................T182, T192
Multimodal Neuoimaging................23, 41
Multivariate................W142
Mu-Opioid Receptors................M51, M254, M260, T51, W83
Muscarinic Acetylcholine Receptor................M177, T45
Myelin................W185
Myelin Imaging................23.3
Myocardial Infarction................T156
Myoinositol................T104
N
NAc core................T58
N-acetylaspartate................M199, W163
N-acetyl-cysteine................4.3
NAD+ and NADH................4.2
Naltrexone................M139, M231, T254, W229, W232, W260
Negative Affect................46.2
Negative Symptoms................M188, M218, T167, T168, W165
Neruopil................M196
Nest-Building................M220
Network Analysis................34.2, 50.2, T180
Network Science................24.3, 53.4
Networks................M22
Neural Circuitry................T37
Neural Circuits................51.3, 61, M224
Neural Complexity................T162
Neural Development................T97
Neural Network Connectivity................T32
Neural Populations................T2
Neuregulin-3................59.1, 59.2, W241
Neuroactive Steroid................M76
Neuroanatomy................M13, M45
Neurobiology................M106, M108
Neuroblast................13.1
Neurochemistry................M190
Neurocircuitry................T154, T184, W153, W164
Neurocircuit................s18, 18.2, T110
Neurocognition................41.2, M189, T65, T123, T169, W107, W180
Neurodegeneration................M3
Neurodegenerative Disease................T86, T95, W3
Neurodevelopment................55, M196, T96, T154, T192, W28, W153, W206
Neurodevelopmental Disorders................M62, T86, W29, W30, W132
Neuroeconomics................T144
Neuroendocrine................46
Neuroendocrine Responses................W9
Neurogenesis................T79, W95
Neurogenesis Enhancers................M5
Neurogranin................W37
Neuroimaging................34.2, 42.2, M42, M47, M79, M170, M198
Neuroimmune................31.4, M49, T21, T260
Neuroimmune Interaction................38, 47.4, T52
Neuroimmunology................47.1, 58.2, T142
Neuroinflammation................58.4, M77, M83, M111, W1, W259
Neurological Disorders................M133
Neuromodulation................17.1, T107, W116, W178
Neuron Subtypes................49
Neuronal Epigenome................T176, W193
Neuronal Maturation................13, 13.3
Neuronal Tracing................13
Neurons................25.3, M196, T216
Neuropathic Pain................33.1
Neuropeptide Y................M11, M65
Neuropeptides................M104, T231
Neurophysiology................24.1, 48.2
Neuroplasticity................17, 48.2, M249, T21, T93, T126
Neuropsychiatric Disorders................38.1, 59.4, T27
Neuropsychiatry................W152
Neuropsychology................38.3
Neuropsychopharmacology................W126
Neurostimulation................6, 21.1, 51.2, T118
Neurosurgery................W14
Neurotechnology................W150
Neurotensin................M9
Neuroticism................W57
Neurotransmitter Release................55.3
Neurotransmitters................M195
Next Generation Sequencing................5.2, W193
Nicotine................52.3, M229, T147, T235, T268, W224, W245, W253, W259, W264
Nicotine Addiction................M266, T237, T243, T251, T266, W251, W262
Nicotine Dependence................M244, M268, T219, W241, W262
Nicotinic................T64
Nicotinic Acetylcholine Receptors................5.1, M244, T145, T235, W261
Nitric Oxide Donor................W209
Nitrous Oxide................W95
NMD................A14, 33.2, 43, 43.3, W57
NMDA Antagonists................11.1, 33.2, W74, W171
NMDA Glutamate Receptors................W106
NMDA Receptor................2, 2.3, 13.2, 14.1, 27.1, 33.1, 33.4, 43.2, 55.2, M58, M193, T91, W189, W238
NMDA Receptor Knockdown................M197
Non Pharmacological Interventions................M108
Non-Human Primate................M147, M182, M201, T232
Non-Pharmacological Therapy................W15
Non-Suicidal Self-Injurious Behavior................32.3
Noradrenaline................M219
Noradrenergic................M7, M158, T253
Noradrenergic System................W247
Norepinephrine................60.1, W218
Novel................M166
Novel Therapeutics................33.4, M177, W126
Novel Tool................M133
Novelty Seeking................W159
Nucleus Accumbens................15.3, 52.3, 54.3, M44, M70, M226, T47, T60, T224, T244, W238, W240, W244, W250
Nucleus Accumbens Shell................T58, W263
O
Obesity................61.3, M41, T99, T146, W137, W147
Obsessive-Compulsive and Related Disorders................W14
Obsessive-Compulsive Disorder (OCD)................33, 33.4, 47, 47.1, 47.2, 61.1, T74, T78, T143, W13, W16, W18, W21, W142
Obstetric Complications................M167
Off-Target................35.1
Oligodendrocytes................23.3, T100
Omega-3 Fatty Acid................T131, W50, W77, W214
Opiates................M139
Opioid Antagonist Treatment................W243
Opioid Dependence................19, M230, M231, W243
Opioid Overdose................19
Opioid System................M51, T49
Opioid Tolerance................W246, W249
Opioid Withdrawal................44.4
Opioids................57.3, T53, T238, T257
Opposite Defiant Disorder................M29
OPRM1 A118G................T114
OPRM1 Gene................T254
Optogenetics................24.1, 24.2, 27.2, 39.1, 40, 40.4, 51, M10, M15, M84, M164, T6, T55, W18, W70, W221, W247
Orbitofrontal................M222
Orbitofrontal Cortex................T242, W41, W253
Orexin................T48
Orexin Receptor Antagonist................T48, T218, W71
Organic Cation Transporters................T229
Outbred Mice................T66
Outbred Rats................1.1
Oxidative Stress................4, 4.2, 4.3, 4.4, 27.3, M204, W141, W176, W265
Oxytocin................15.3, 44, 44.1, 44.2, 44.3, 44.4, M35, M122, M146, M155, M251, T34, T75, T82, W2, W19, W122, W198, W235
P
P11................M89
P2X7................M111, T108
P38 MAPK................M153
P50................T90
PACAP................7.4, 26, 26.1, 26.2, 26.3, 43
Pain................3.3, 11.3, M213, W75, W255
Pain Observation................30.3
Palpitation................T1
PANDAS................47.1, 47.2, 47.3, 47.4
PANSS Inconsistencies................M165
Parental Age................W35
Parkinson's Disease................54.1, 54.2, M65, M89, M154, T147
Parvalbumin................4.4, 27, 27.3, 27.4
Parvalbumin Interneurons................9.3, T38, T181, T183, T217, W244
Patch Clamp Recording................T105
Patch Foraging................M1
Paternal Stress................57.4
Pathology................M210
Pathophysiology................50.2
Pavlovian Conditioning................W56
PCaMKIIa................M205
Pediatric Acute-Onset Neuropsychiatric Syndrome................47, 47.1
Pediatric PTSD................W28
Pediatrics................61, 61.2, 47.2
Perception................M194, M208
Periaqueductal Grey (PAG)................12.2
Perineuronal Nets................4, 4.4, 27.4, T217
Peripartum................M122
Peripheral Blood Mononuclear Cells................M105, T130
Personality................40.2, M94, M103, M128, W14, W66
Positron Emission Tomography (PET) Imaging................8, 32.1, M12, M53, M77, M105, M111, M128, M133, M135, M144, M169, M182, M264, T17, T74, T169, T245, T248, W1, W113, W140, W155, W194
PET Study................W44
PFC................T251
PGE1................M148
Pharmacogenetic Response................T236, T254, W43, W173
Pharmacogenetics................40.4, M69, T114, T194, T246, W229
Pharmacogenomics................W68
Pharmacokinetics................T232
Pharmacology................M23, T115, W151
Pharmacotherapy................T104, T228, T240
Pharmacovigilance................W63
Phase III Trial................M173, M180
Phenotypic Screening................25, W161
Phenotyping................25.3
Phosphodiesterase-4 (PDE4)................M120
Phosphorylation................M175
Photoidentification................T2
Placebo................M163
Placebo Response................11, T73, T129
Placebo-Controlled Trial................T73
Placenta................7.2, M167
Plasticity................16.3, T34
POGZ................T97
Polydrug Use................M225
Polygenetic Risk Score................38.2, M167, W49, W173
Polygenic................T41
Polygenic Risk................50.2
Polygenic Risk Score................38, M140, T203, W3
Population and Single-Cell Scales................49.1
Population -Based................M142, W35
Population Genetics................T213
Positive Allosteric Modulators................W261
Positive and Negative Syndrome Scale................T195
Positive Emotion................60.2
Positive Mood................T32
Positron Emission Tomography (PET)................54.1, M68, M119, M120, M168, M209, W147, W254, W259
Postmortem................M197, W175
Postmortem Brain Tissue................23, 38, M106, M184, T164, T193, W3, W193, W200
Postmortem Human Brain................20.3, 27.4, M4, M38, M104, T39, T109, W144
Postpartum Blues................T120
Postpartum Depression................M76, M122
Posttraumatic Memory Deficit................M149
Poverty................42.4
Prader Willi Syndrome................M35
Precision Medicine for Depression................W68
Prediction................32.3, 53.3, M34, M185
Predictive Models................53
Predictive Validity................25.1
Predictors................W93
Predictors of Response................6.4, T31
Prefrontal Circuit................13.3, T135
Prefrontal Cortex................5.2, 7.1, 10.2, 12.1, M2, M15, M95, M138, M250, T14, T202, T235, T263, W116, W213, W238
Pregnancy................M122, M137, T90, T96, W63
Prenatal................M86
Prenatal Ethanol................M33
Prenatal Smoking................W231
Prenatal Stress................7.2, 42.3
Prenatal Stress-Immune Model................7.3
Prescription Opioids................19
Presynaptic Ca2+ signaling................55.3
Presynaptic Uptake................M151
Preterm................42.2
Prevention................32, T120
Prevention of Alzheimer's Disease................M5
Primary Neuron................M247
Prodrome................53.1, M185, T120
Prodynorphin................W250
Proenkephalin................W250
Progesterone................18.1, W231
Projection Targets................49.1
Proopiomelanocortin Neurons................M33
Propanolol................M158
Protein Complexes................W239
Protein Expression................T193
Protein Kinase C................43.2, T255
Protein Structure................22.2
Protein Structure and Function................22
Proteomics................W200
Proton Magnetic Resonance Spectroscopy................M32, M125, M157
Proximity Ligation Assay................M256
PSD95................2.2
Psychiatric Comorbidity................40.2, M125, M202, T125, T238, W48
Cognitive Function................W207
Psychiatric Disorders................W207
Psychiatric Genetics................20.3, M90, T159, W203
Psychiatric Measurement................32.2, T214
Psychopathology................W202
Psychopathology Patterns................T206, W35
Psychopharmacology................1, 6, M61, M209, T215, W125, W215
Psychophysiology................M19, W10
Psychosis................4.1, 10, 10.2, 10.4, 29.1, 34, 53.1, M53, M162, M215, M246, T39, T203, W185, W204, W210, W211
Psychosis and Memory................2.4
Psychosis Continuum................T160
Psychosis Risk................56.3, M188
Psychosocial Stress................42.1, M53, M227
Psychostimulants................9.3, 30.4, 44.1, 54.3, T229
Psychostimulation................W264
Psychotherapy................M8, T4
Psychotic Disorders................22, 53.2, M185, W184
Psychotropic Medications................T190
PTEN................10.4
Posttraumatic Stress Disorder (PTSD)................7.4, 12.2, 18.4, 33.1, 39, 39.4, 53.4, 59.4, M6, M8, M11, M12, M19, M56, M92, M127, M192, M219, T4, T8, T10, T67, T68, T72, T73, T111, T248, T256, W7, W8, W10, W109, W134, W218
PTSD Depression................T7
Puberty................M21, W26
Publications................45
Punishment................M248
Purkinje Cells................51
Pyramidal Neuron................T38
Q
QIDS-SR16................W93
QOL................T152
Quantitative Electroencephalography (qEEG)................11.1, T16, T28
Quantitative Trait Locus (QTL)................M20, T249
R
R-(-)-Ketamine................56, 56.3, M115, M118, M121
R-(-)-Norketamine................M121
Racemic Ketamine and Metabolites................56
Racial/Ethnic Minority Elderly................M142
Radiation Injury Non-Human Primate................M147
Radiotracer................M111
Randomized Clinical Trial................T73, T87, W134, W208
Randomized Trial................W192
Rapid Antidepressant................6.2, T135
Rapid Antipsychotic Augmentation................W209
Rat Model................T122
Rating Scales................T101, T214
Rats................T127, T145, T216, T250
RDoc................W72
Real-Time fMRI................W69
Recent Onset Psychosis................W216
Receptor Internalization................W194
Trafficking................W194
Recovery................T182
Recurrence Risk................W105
Redox Dysregulation................4.2, 27, T208
Reelin................55.1, 55.2, 55.3
Reinforcement................T50
Reinforcement Learning................T198, W79
Reinforcement-Based Decision-Making................30.2, M46
Reinstatement................26.2, 39.2, 39.4, M227, T243, W234
Rejection................W83
Relapse................39, 39.2, M42, M268, T25, T222, T239, W18, W93
Relapse and Hospitalization................T115
Relapse and Treatment Outcome................T53
Relapse Prevention................T195, W231
Religion................W128
Remifentanil................M229
Remote Assessment Solution................T195
Remote Memory................W20
Repeated Social Defeat................31.2
Repetitive Transcranial Magnetic Stimulation................T7, W36
Reproducibility, Design, Replication................25.1, T18
Research Domain Criteria (RDoC)................M136, T57, T111, W12, W52, W107
Residency Training................28, W85, W125
Resilience................60, 60.1, 60.3, M11, M18, T67, W24, W94, W141
Response Inhibition................16.2
Rest fMRI................3.2
Resting State................21.2, 21.3, M178, M214, T150
Resting State Brain Imaging................T226
Resting State fMRI................M70, M98, W24, W115, W119
Resting State Functional Connectivity................3.1, 6.2, 21, 21.1, M24, M39, M74, M107, M131, M169, T7, T18, T44, T62, T77, T80, T135, T143, T219, W13, W21, W99, W142, W211, W216, W245, W260
Resting State Intrinsic Connectivity................T146
Retina................M63
Reversal Learning................W26, W190
Reward................3.4, 18.2, 41.4, 54, M48, T60, W82, W223
Reward and Aversion................54.4, M130, T55
Reward Deficit................W115
Reward Devaluation................T99
Reward Neural Circuitry................41, 42.1, 61.3, M21, M253, T173
Reward Prediction Error................W41, W79
Reward Processing................T233
Reward Prospect................M240
Reward System................M43, M260, T105, W165
Reward-Based Decision-Making................M1, T53, T241, W112, W190, W252
Rhesus................W133
Rho Family GTPase................T149
Risk................M107, T30
Risk and Resilience................15.1, T53, T136
Risk-Based Monitoring................M165
Risk-Reward Paradigm................W112
Risperidone................M29, W214
RNA Sequencing................9.2, 20.3, 23.3, 38.4, M87, W80, W144, W156, W188
RNA-seq................20.4, 31.4, 49.1, M49, M117, T35, T100, T184, T208, W121
Roadmap................M8
Rodent................s26, M148
rTMS................21, 21.2, T113, W254
S
Safety................M150
SAGE-547................M76
Salience Network................T158, T173, W21
Schizoaffective Disorder................T162
Schizophrenia................2, 2.2, 4, 4.1, 4.2, 8.4, 10.3, 11, 11.1, 16, 16.2, 16.3, 22.1, 22.4, 24.4, 27, 27.2, 27.3, 27.4, 33, 33.3, 34.3, 36, 36.1, 36.4, 38.3, 50, 50.3, 51, 51.2, 55.4, 58, 58.2, 59.3, M161, M163, M164, M165, M166, M167, M169, M170, M172, M173, M174, M175, M176, M177, M178, M180, M181, M183, M184, M186, M189, M191, M192, M194, M198, M200, M202, M203, M204, M205, M206, M207, M208, M209, M211, M213, M216, M217, M218, M268, T36, T38, T41, T43, T45, T161, T162, T163, T165, T167, T168, T171, T174, T175, T177, T178, T179, T181, T185, T186, T187, T189, T190, T193, T195, T196, T197, T199, T200, T201, T202, T204, T205, T207, T213, T214, T215, T217, T237, W160, W161, W162, W163, W165, W166, W169, W172, W176, W177, W178, W181, W182, W183, W187, W188, W191, W192, W194, W195, W197, W200, W206, W209, W212, W213, W215, W241
Schizophrenia Genetics................38.2, M140, W179
Schizophrenia Prodrome................W170, W217
Synaptic Aberrations................2, 2.2, 22.1, 58.2, M184, T45, W213, W241
Technology................M55, M206, T197, W161
Schizophrenia-Like Behavior................59, M112, M171
Schizotypy................T160
Screening................32
Seizures................T156
Selectively Bred bHR And bLR Rats................T249
Self-Administration................44.1, 57.3, M48, M223, M227, M229, M244, T48, T224, T234, T243, T247, W256
Self-Directedness................M159
Self-Injurious Behavior................W143
Self-Other Processing................W197
Self-Relatedness................16.1
Semantic................53.1
Sensorimotor Gating................T172
Sensory Data................W123
Sensory Overload................22.4
Sensory Processing................W169
Serious Mental Illness................1, W136
Serotonergic Neuron Subtypes................49.1
Serotonergic Neurons................49.3
Serotonin................49, 49.3, 49.4, M57, M135, M153, M247, T126, W5, W76
Serotonin 1A Receptor................23.4, 49.2
Serotonin 1b receptor................M105, W47
Serotonin 2A................M131
Serotonin 5-HT2C Receptor................M259, W239
Serotonin 5-HT7................49.2
Serotonin and Norepinephrine Reuptake Inhibitor................W68
Serotonin Transporter................M153, W113
SERT................W155
Serum Levels................M181
Sex Differences................5, 7.2, 7.3, 12.1, 12.4, 18, 18.3, 31.4, 57.2, M3, T26, T68, T69, T146, T153, T233, W46, W55, W60, W61, W84, W87, W92, W98, W122
Sexual Dimorphism................5.3, 7, 12.2, 18.1, 46.2, M59, M97, M112
Sexual Sadism................30.3
Shank................322.4
Short-Term Synaptic Depression................M201
shRNA................W266
SIBAT................M113
Sigma 2................M218
Signal Transduction................5.2
Sign-Tracking................M226
Simulated Driving................M132
Simultaneous PET-MR................M144, T51
SK3 Calcium-Activated Potassium Channels................M84
Skin Conductance Responses................T71
Sleep................1.2, 36, 36.3, 36.4, M48, M71, M220, M221, T19, T68, T216, W220
Sleep Disturbance................M60, M219, T79, W192
Sleep Spindles................W219
Slow Oscillation................43.1
Smartphone-Based App................W123
Smoking................W187, W259
Smoking Cessation................M252, M255, W262
SNP................W179
SNX19................20.4
Sociability................T91
Social Anxiety................12.4, M14, M16, T125, W122
Social Behavior................15.3, 18.1, 51.1, M155, T82, T138, W61
Social Buffering................M10
Social Cognition................M146, T44, W197, W198, W243
Social Cognitive Skills Training................34.3
Social Communication................M158
Social Defeat Stress................12.3, T110, W122
Social Defeat................W11
Social Deficits................34.1
Social Functioning................15, 34.2, T87, T203
Social Interaction................26.1, M17
Social Isolation................M84
Social Stimuli................W32, W83
Social Stress................T59
Social Support................W235
Socio-Economic Status................W227
Somatic Mosaicism................20, 20.1, 20.2
Somatic Mutation................20.2, T164
Somatosensory Network................T146
Somatostatin................14.1, 14.4
Source Based Morphometry................30.3
Spatial Navigation................W168
Speech................53, 53.2
Speech Production................53.3
Spines................2.2
SSRI................1.3, M62, M72, M264, W82
Statistical Methods................M225
Stem Cells................10.2, 49, M196, W132
Stereotypic Behavior................T91
Stereotypy................W143
Sterols................M91
Streptococcus Pyogenes................47.3
Stres................s12, 15.1, M106, M108, T34, T202, W18
Stress Abnormalities................M33
Stress Models................M87, T22, T231
Stress Response Circuitry................M75
Striatum................9.3, 41.4, 54, 54.4, 57.2, M21, M253, T153, W194
Structural Covariance................M22
Structural MRI................29.2, T103, T180, W7, W28, W108, W179
Subcellular Fractionation................T201
Subclinical Psychosis................34.1, M178
Subcortical Shape Analysis................W108
Subgenual................M74, T144
Subgroups................T166
Subjective Cognitive Impairment................M5
Subjective Response................T264, W232
Substance Abuse................3, 9, T13, T240, T257
Substance Use................3.2
Substance Use Disorder................M265
Substance-Related Disorders................40.3, M59, M267, T248
Subthalamic Nucleus................W13
Subtypes................M170, T41
Suicidal Ideation................M113, W97
Suicide................23, 23.1, 23.2, 23.4, 32.2, 32.3, 32.4, M71, M73, M123, T19, T33, T109, T136, T138, T140, W50, W84, W128, W136
Suicide Assessment................32, T12, T134, W50
Suicide Behavior Severity................32.1
Superior Frontal Cortex................T201
Superior Longitudinal Fasciculus................M215
Susceptibility Genes................M257
Swine Model................T59
Sydenham's Chorea................47.3
Symptom Trajectory................M163
Symptoms................W160
Synapses................15, 22, 38.1, 58, 59.3, M183, M192
Synaptic Cleft................22.2
Synaptic Density................M119
Synaptic Function................58.3, W117
Synaptic Organizer................22.2
Synaptic Plasticity................2, 2.1, 5.3, 9.1, 15.2, 55, 55.4, 56.1, 59.1, M49, T61, T212, W244
Synaptic Protein Interaction Network................22.2
Synaptic Pruning................22.3, 58.4, T170
Synaptogenesis................22.1, 22.3
Synchrony................W222
Synthetic Cannabinoids................M246
Synthetic Psychoactive Cathinones................W248
T
TALEN................35.1
Tardive Dyskinesia Clinical Trials................M150
Target................34
Task-Based Functional Connectivity................M261
Tau................T63, W37, W130
TBI................M149, M219, W155
TBR1................13.1
TBX1................T92
Telomere................T140, W6
Temperament................M159
Temperature Regulation................W248
Th17................58.1
Th17 Cells................47.3
Thalamus................27.3, 27.4, T36, T174, T252, W119
Thalamus - Reticular Nucleus................27, 27.1, 27.2
THC................M245, T220, T267, W202
Therapeutic Drug Monitoring................M181
Therapeutics................4.1, 10
Therapy-Resistant Depression................M67, W54
Threat................40.3, T54
Threat of Shock................T54
Tianeptine................M51
Time................T176
Timing................M156
TMS Targeting................W103
Tobacco................M238, M255, W259
Tobacco Smoking................M236, M257, T56, T151, T226, W245
Tolcapone................M212, W152, W157
Tolerability................M150
Tonic Inhibition................48
Top-Down Control................M141, T170
Toxicology................W175
Trace Amine-Associated Receptor 1................36.1, 36.2, T173, T243
Trace Amines................36, 36.3, 36.4
Tract Tracing................13.1
Tractography................6.3
Training................W189
Trajectories................M230
Transcranial Direct Current Stimulation (tDCS)................17, 17.1, 17.2, 41.1
Transcranial Magnetic Stimulation (TMS)................21.1, M32, M186, M222, T28, W103
Transcript Isoforms................20
Transcription Factors................49.3
Transcriptome................50.2, M104, T26, T56
Transcriptome Biology................50.4
Transcriptomics................M26, T35, T148
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)................W15, W89
Transdiagnostic................61
Transdifferentiation................49.3, T188
Transgenerational................57, 57.3, 57.4, M137
Translational Neuroscience................28, 37, 60, M23, M95
Trans-Synaptic Bridges................22.2
Trauma................W8
Trauma And Stress Disorders................M56
Trauma Exposure................M262
Traumatic Brain Injury................24, 46, 46.4, W49, W152, W157
Traumatic Stress................M11, M18
Treatment................M218, T53, T132, T215, T253, W29, W77
Treatment Adherence................T189
Treatment Outcome................6.4, 41.2, M93, T182
Treatment Outcome Prediction................M55
Treatment Resistance................W101
Treatment Resistant Depression................6, 6.2, 6.3, M56, M66, M80, M93, M96, M115, T28, T33, T113, T122, W74, W119
Treatment Response................W180, W216
Treatment Target................s41
Treatment-Resistant Schizophrenia................T194, T210
Trichotillomania................T104
Triple-Deuterated L-Dopa................M154
TrkB................M223, T83
TSPO................58.4, M77, W155
TSPO and [11C]PBR-28 PET................M83
TSPO VT................T74
Twins................T206
Two-Photon................43.1
Type-2 Diabetes................T211, W4
U
Ubiquitination................W176
Unaffected Relatives................W184
Unpredictable Stress................T223
V
Vagus Nerve Stimulation................M263
Valence................M9, T2
Varenicline................M268, W261
Vasopressin................T87
VEGF-R2................M148
Ventral Attention................T44
Ventral Hippocampus................M15, T110, W70
Ventral Pallidum................T50, W263
Ventral Striatum................M169, M240, W18
Ventral Tegmental Area (VTA)................9.2, 15.3, M211, M220, T61, T174, W131, W257, W263
Ventrolateral Striatum................T157
Ventromedial................3.3
Verbal Episodic Memory................T94
Veterans................W84
Vilazodone................M126
Violence................T11, T81
Visual Contrast Sensitivity................W217
Visual Cortex................T170
Visual Information Processing................W217
Visual Perception................W199
Visuospatial Working Memory................M203
Vitamin E................M147
VLDLR................55.2
vmPFC................11.4, W16
Voltage-Gated Calcium Channel................W90
Voltammetry................24.2, T58, T105
Voxel-Based Morphometry (VBM)................T57, T242, W204
Vulnerability................T206
W
Wakefulness................M220
Weight Gain................M29
Weight Loss................W137
White Matter................M110, M215, W42, W59
Whole Exome Sequencing................T159, T164
Whole Genome Sequencing................23.3, 40
Withdrawal................M252, T151, T220, T247, W267
Within-Pair Concordance................T206
Wnt Signaling................5, M156
Women's Mental Health................W63, W88
Word List Recall Test................T94
Working Memory................24.1, 29.1, T45, T76, T92, T191, T207, T250, W107, W167
X
Xct................43.4
Y
Young Adults................29.2, M239, W267
Youth................34.2, M34
Z
Zebrafish................M23
Zinc-Fingers................15.4
B-Arrestin................M187
Γ Oscillation................T209
ΔFosB................T110
Rights and permissions
About this article
Cite this article
ACNP 55th Annual Meeting: Keyword Index. Neuropsychopharmacol 41 (Suppl 1), S679–S698 (2016). https://doi.org/10.1038/npp.2016.244
Published:
Issue Date:
DOI: https://doi.org/10.1038/npp.2016.244